Madrigal Pharmaceuticals ... (MDGL)
NASDAQ: MDGL
· Real-Time Price · USD
422.99
-3.85 (-0.90%)
At close: Sep 25, 2025, 3:59 PM
422.99
0.00%
After-hours: Sep 25, 2025, 04:18 PM EDT
-0.90% (1D)
| Bid | 305.66 |
| Market Cap | 9.43B |
| Revenue (ttm) | 515.55M |
| Net Income (ttm) | -281.9M |
| EPS (ttm) | -12.63 |
| PE Ratio (ttm) | -33.49 |
| Forward PE | 115.15 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 546.34 |
| Volume | 182,200 |
| Avg. Volume (20D) | 385,485 |
| Open | 424.82 |
| Previous Close | 426.84 |
| Day's Range | 421.06 - 429.13 |
| 52-Week Range | 200.63 - 457.16 |
| Beta | -1.02 |
| Ex-Dividend Date | n/a |
About MDGL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MDGL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MDGL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMadrigal Pharmaceuticals Inc. is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+8.59%
Madrigal Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
2 months ago
+10.87%
Madrigal Pharmaceuticals shares are trading higher after the company received a Notice of Allowance from the US Patent and Trademark Office for a new patent covering Rezdiffra.
1 month ago · seekingalpha.com
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow FurtherRezdiffra's Q2 '25 net sales surged 55% to $212.8M, beating expectations and highlighting strong commercial momentum for Madrigal Pharmaceuticals, Inc. Despite robust revenue growth, Madrigal Pharmace...
1 month ago · seekingalpha.com
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call TranscriptMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Soergel - Executive VP & Chief Medical Officer Mardi C. Dier - Execu...
